Two experiments were conducted with young pigs to determine the efficacy of ornithine (Orn) or citrulline (Cit) as precursors of arginine (Arg). In Exp. 1, pigs were individually fed an Arg-deficient, semipurified diet (.18% Arg) supplemented with .3% Arg or an equimolar quantity of Orn or Cit. Supplemental Arg or Cit increased rate and efficiency of weight gain, but Orn addition was without effect. Free Arg in plasma 3 h post-prandial was increased by addition of either Arg or Cit to the basal diet. Liver Arg was elevated by dietary addition of Arg, Orn or Cit; kidney Arg and Orn were elevated only in pigs receiving supplemental Cit. Arginine or Cit addition to the diet increased Arg concentration in muscle tissue, but muscle Orn was unresponsive to any of the supplements fed. In Exp. 2, pigs were again fed the Arg-deficient, semipurified diet supplemented with .3% Arg or four times an isomolar quantity of ornithine. Arginine addition to the diet increased weight gain and feed efficiency, while Orn supplementation was without effect. Plasma Orn was increased by excess Orn, while plasma Cit was unaffected by supplemental Arg or Orn. Moreover, excess Orn increased free Orn and proline (Pro) in liver, kidney and muscle. Free Cit, however, increased only in liver from feeding excess Orn. In addition, excess Orn decreased both plasma ammonia and free glutamine (Gln) concentration in brain. Arginase activity was roughly 10, 40 and 100 times greater in hepatic tissue than in renal cortex, renal medulla or intestinal mucosa, respectively, while hepatic ornithine transcarbamoylase (OTC) activity was about 15 times greater than the activity present in mucosa tissue. Renal OTC activity was too low to be accurately measured.

No abstract

Rat bioassays revealed that protein quality of a commercial. enteral product was not affected by carbohydrate (CHO) content, heat treatment or storage. Slope-ratio regression analysis of weight gain yielded lysine (LYS) and sulfur amino acid (SAA) bioavailability estimates of 96.7% and 100.0% (relative to crystalline sources of LYS and SAA), respectively, regardless of CHO content or heat treatment.With storage of the products for 1 year, a 10% decrease in LYS bioavailability occurred in those products containing CHO with dextrose equivalency values 5 17.3. LYS bioavailability in the products with lower reducing sugar content was not affected by storage. SAA bioavailability was not affected by storage, regardless of CHO content.

No abstract